Azacitidine MTD

Phase 2Small molecule

MM.D. Anderson Cancer Center

Azacitidine MTD is one of 23 small molecule programs targeting Lymphoblastic Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoblastic LymphomaRecruiting

Lymphoblastic LymphomaPhase 2

Recruiting

Competition

Competitive Landscape

23 competitors in Lymphoblastic Lymphoma

#DrugCompanyPhaseTrials

Cytosar

Teva

Approved

5 2

Trexall

Jazz Pharmaceuticals

Approved

5 3

Oncovin

Eli Lilly

Approved

3 4

Dacogen

Sun Pharmaceutical Industries, Inc.

Approved

2 5

Cytoxan

BBaxter Healthcare Corporation

Approved

5 6

Tabloid

Akero Therapeutics

Approved

5 7

Purinethol

SStason

Approved

4 8

Ninlaro

Fludara

Cerubidine

HHikma Pharmaceuticals LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Lymphoblastic Lymphoma

NCT06686108

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

Azacitidine and CAPOX in Metastatic Colorectal Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01193517·26 enrolled

Lymphoblastic Lymphoma1 trial

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

Recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT06686108·59 enrolled

Myelodysplastic Syndrome1 trial

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02269280·185 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Azacitidine MTD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azacitidine MTD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azacitidine MTD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

Azacitidine MTD

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

Lymphoblastic Lymphoma1 trial

Myelodysplastic Syndrome1 trial

References

Drug Info

Quick Facts

Related News